---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-007468"
form_type: "8-K"
ticker: "MGRX"
cik: "0001938046"
company_name: "MANGOCEUTICALS, INC."
filed_at: "2026-02-19T23:59:59+00:00"
generated_at: "2026-05-16T01:49:49.748511+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# MangoRx's new $99/mo injectable TRT sees 336% MoM sales growth, 54% CAC drop

## Summary
- Month-over-month sales of injectable TRT program increased 336% since mid-December 2025 launch.
- Customer acquisition cost reduced by 54% over the same period.
- Global TRT market valued at $2.11-2.2B in 2025, expected CAGR 3.9% (TBRC report).
- CEO Jacob Cohen: TRT is key strategic focus; platform evolving to broader men's health.

## SEC filing metadata
- accession: 0001493152-26-007468
- form_type: 8-K
- ticker: MGRX
- cik: 0001938046
- company_name: MANGOCEUTICALS, INC.
- filed_at: 2026-02-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1938046/000149315226007468/0001493152-26-007468-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1938046/000149315226007468/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-007468
- JSON: https://secwatch.observer/filing/0001493152-26-007468.json
- Plain text: https://secwatch.observer/filing/0001493152-26-007468.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.